Latest News

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
04/14/15AcelRx Pharmaceuticals Announces Presentation Of Sublingual Sufentanil Data At The Society of American Gastrointestinal and Endoscopic Surgeons Meeting
Clinical Data from Two Different Development Programs Highlight Efficacy and Tolerability of Sublingual Sufentanil in Out-patient and In-patient Surgical Populations REDWOOD CITY, Calif., April 14, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a poster presentation will be made at the Annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting to be held April 15th to April 18th, 2015 at the Gaylord Opryland Resort and Convention... 
Printer Friendly Version
03/20/15AcelRx Appoints Howard B. Rosen as Interim CEO
AcelRx Announces Restructuring to Focus on Regulatory Approval of Zalviso and Clinical Development of ARX-04 REDWOOD CITY, Calif., March 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced the appointment of Howard B. Rosen as interim Chief Executive Officer of AcelRx, effective April 1, 2015. Mr. Ros... 
Printer Friendly Version
03/16/15AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04
SAP301 Trial to Study Sufentanil Sublingual Single-Dose Tablet for the Treatment of Moderate-to-Severe Acute Pain REDWOOD CITY, Calif., March 16, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04. ARX-04 is a non-invasive, single-use 30 mcg sufenta... 
Printer Friendly Version
03/09/15AcelRx Provides Regulatory Update on Zalviso
REDWOOD CITY, Calif., March 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided an update on the timing and potential content of the resubmission of the New Drug Application ("NDA") for Zalviso. AcelRx late last week received correspondence from the Food and Drug Administration ("FDA") stating that in addition to... 
Printer Friendly Version
03/09/15AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
REDWOOD CITY, Calif., March 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported financial results for the three and twelve months ended December 31, 2014.     Fourth Quarter 2014 Financial Results Net loss for the fourth quarter of 2014 was $13.8 million, or $0.32 basic and diluted net loss per share, compared... 
Printer Friendly Version
03/04/15AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015
REDWOOD CITY, Calif., March 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter and yearly 2014 financial results after market close on Monday, March 9th, 2015. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific... 
Printer Friendly Version
02/20/15AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events
REDWOOD CITY, Calif., Feb. 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E. Morris, chief financial officer will be presenting at RBC Capital Markets' Global Healthcare Conference and Cowen and Company's 35th Annual Healthcare Conference.  Details of the two presentations are as follows: ... 
Printer Friendly Version
02/04/15AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference
REDWOOD CITY, Calif., Feb. 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E Morris, Chief Financial Officer, will present a company overview and update at the 17th Annual BIO CEO & Investor Conference. Details of the presentation are as follows: BIO CEO & Investor Conference Dat... 
Printer Friendly Version

AcelRX

CONTACT